Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society.

Despite the fact that an estimated 60 million people worldwide suffer from neurodegenerative diseases, a population expected to double every 20 years, there are currently no approved disease-modifying therapies or cures available. These diseases devastate patients and their loved ones.

Yumanity is dedicated to protecting the vitality of the mind. Using innovative technology licensed from Susan Lindquist’s laboratory at MIT’s Whitehead Institute, we are working to identify and develop new, disease-modifying therapies for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

LEARN MORE

Yumanity scientific co-founder, Chee Yeun Chung, Ph.D., provides an overview of protein misfolding at the 2017 TEDMed “The Hive” conference.

 

PRESS RELEASES

December 4, 2018

Yumanity Therapeutics Announces Publication of Paper in Cell Reports Detailing a Potential New Therapeutic Target for the Treatment of Parkinson’s Disease

VIEW MORE

LATEST NEWS

November 26, 2017

Tony Coles comments on the environment for raising capital for neurodegenerative disease research

VIEW MORE

November 20, 2017

Scientific co-founder, Dr. Vikram Khurana, published for investigation into protein misfolding biology and pathology

VIEW MORE

November 16, 2017

Dr. Ken Rhodes, explains method of using yeast to understand the protein misfolding associated with neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS BioCentury

VIEW MORE

ARCHIVE